Increase/Decrease in Cash: The total change in cash for the company over the given period.
Oxford BioMedica (OXBDF) had Increase/Decrease in Cash of $-28.15M for the most recently reported fiscal quarter, ending 2024-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$175.28M |
|
$90.36M |
|
$133.90M |
|
$309.18M |
|
$74.65M |
|
$133.14M |
|
$144.64M |
|
$219.29M |
|
$89.89M |
|
$52.04M |
|
$89.89M |
|
105.31M |
|
| Cash Flow Statement Financials | |
$-49.47M |
|
$9.20M |
|
$12.35M |
|
$130.90M |
|
$102.75M |
|
|
Increase/Decrease in Cash |
$-28.15M |
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|